The xF+ Liquid Biopsy Panel is designed to extend the diagnostic capabilities for detecting cancer-related genomic alterations in circulating tumor DNA (ctDNA). Featuring a comprehensive sequencing panel with up to 523 genes, it focuses on identifying mutations not detectable through conventional solid tumor analysis alone. This test provides a unique opportunity to maximize the detection of biomarker presence for targeted therapies, thus addressing a critical area of precision oncology. The addition of liquid biopsy testing enhances early detection, monitoring of disease progression, and evaluation of treatment responses in real-time, for a holistic view of tumor biology.
